TMEM205: A Potential Drug Target Or Biomarker (G374882)

Target Name: TMEM205

NCBI ID: G374882

TMEM205

Other Name(s): TMEM205 variant 1 | transmembrane protein 205 | MBC3205 | Transmembrane protein 205, transcript variant 1 | Transmembrane protein 205 | MGC3205 | MGC110858 | UNQ501 | TM205_HUMAN

TMEM205: A Potential Drug Target Or Biomarker

TMEM205 (TMEM205 variant 1) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the transmembrane protein family and is known for its role in cell signaling and inflammation.

TMEM205 has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and expression pattern have also led to a high interest in its potential use as a therapeutic agent.

TMEM205 is a 21-kDa transmembrane protein that is expressed in the brain, heart, and kidneys. It has a unique structure, with a long N-terminus that is involved in its cell signaling and interaction with other proteins. The TMEM205 protein is composed of two distinct domains: a N-terminal transmembrane domain and a C-terminal cytoplasmic domain.

The N-terminal transmembrane domain of TMEM205 is characterized by a unique structural feature called a \"pseudopod,\" which is a long, flexible region that is involved in the regulation of cell signaling and interacts with other proteins. The N-terminus of TMEM205 contains a putative intracellular loop that is involved in the regulation of its stability and localization to the cell surface.

The C-terminal cytoplasmic domain of TMEM205 is characterized by a unique structural feature called a \"helicase domain,\" which is involved in the degradation of intracellular signaling proteins. The C-terminal domain of TMEM205 contains a single transmembrane alpha helix that is involved in the stability of the protein and its localization to the cytoplasm.

TMEM205 has been shown to play a role in various cellular processes, including cell signaling, inflammation, and autophagy. It has been shown to interact with various proteins, including the transcription factor NF-kappa-B and the protein PDGF-尾.

In addition to its role in cellular signaling and interaction, TMEM205 has also been shown to be involved in the regulation of various cellular processes, including cell division, apoptosis, and angiogenesis. Its unique structure and expression pattern have also led to a high interest in its potential use as a therapeutic agent.

TMEM205 has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and expression pattern have also led to a high interest in its potential use as a therapeutic agent.

In conclusion, TMEM205 is a transmembrane protein that is expressed in various tissues of the body. Its unique structure and expression pattern have led to a high interest in its potential use as a drug target or biomarker for various diseases. Further research is needed to fully understand its role in cellular signaling and interaction, as well as its potential as a therapeutic agent.

Protein Name: Transmembrane Protein 205

Functions: In cancer cells, plays a role in resistance to the chemotherapeutic agent cisplatin

The "TMEM205 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM205 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets